Torrent Pharmaceuticals Ltd

As of June 30, 2026, Torrent Pharmaceuticals Ltd carries a market capitalization of 1.56T, placing it among publicly traded companies globally. Its enterprise value stands at 1.56T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Torrent Pharmaceuticals Ltd's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Torrent Pharmaceuticals Ltd has 338.45M shares outstanding.

As of June 30, 2026, Torrent Pharmaceuticals Ltd trades at a trailing price-to-earnings ratio of 73.95.

As of June 30, 2026, Torrent Pharmaceuticals Ltd trades at an EV/EBITDA multiple of 30.79 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 10.12 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 43.82 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.56T versus a market cap of 1.56T, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 7.66M in revenue per employee across its workforce of 20,173.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Torrent Pharmaceuticals Ltd recorded 7.11B in income tax expense. That works out to an effective tax rate of 24.80, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 28.67B, leaving 21.81B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Torrent Pharmaceuticals Ltd's stock has gained approximately 28.41% over the past 52 weeks. The 50-day moving average sits at 4,846.43, while the 200-day moving average is 4,489.73.

Over the twelve months ended June 30, 2026, Torrent Pharmaceuticals Ltd generated 154.60B in revenue and converted that into 21.81B in net income, yielding earnings per share of 61.79. EBITDA reached 50.81B, while operating income came in at 36.80B.

Over the twelve months ended June 30, 2026, Torrent Pharmaceuticals Ltd posted a gross margin of 75.57, reflecting its pricing power and cost economics. The operating margin of 23.80 and net profit margin of 14.11 provide insight into operational efficiency.

Torrent Pharmaceuticals Ltd's most recent stock split took place on July 8, 2022 with a 1:2 split ratio.